Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press17810.17650/1994-4098-2011-0-3-56-64GYNECOLOGY. PROBLEMГИНЕКОЛОГИЯ. ПРОБЛЕМАEarly ovarian cancer: our view of the problemРанний рак яичников: наш взгляд на проблемуZhordaniaK. I.ЖорданиаК. И.
Russian Federation
KhokhlovaS. V.ХохловаС. В.
Russian Federation
svkhokhlova@mail.ruCancerogenesis Research Institute, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowНИИ клинической онкологии РОНЦ им. Н.Н. Блохина РАМН, Москва140820113566418082014180820142011https://ojrs.abvpress.ru/ojrs/article/view/178

The paper considers some pathogenetic aspects of ovarian tumor development, on the basis of which the authors recommend to perform more aggressive chemotherapy in patients with the so-called early stages of ovarian cancer.

В статье рассматриваются некоторые патогенетические аспекты развития опухолей яичников, на основании которых авторы рекомендуют проводить более агрессивную химиотерапию больным, страдающим так называемыми ранними стадиями рака яичников.

early ovarian cancerpathogenesismetastasestreatmentранний рак яичниковпатогенезметастазылечение1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2008;19(2 Прил 1).Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2008;19(2 Прил 1).2. Карселадзе А.И. Морфология эпителиальных опухолей яичников. Автореф. дис. ... д-ра мед. наук. М., 1989.Карселадзе А.И. Морфология эпителиальных опухолей яичников. Автореф. дис. ... д-ра мед. наук. М., 1989.3. Kindelberger D.W, Lee Y., Miron A. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161–9.Kindelberger D.W, Lee Y., Miron A. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161–9.4. Глазунов М.Ф. Опухоли яичников. Л., 1961.Глазунов М.Ф. Опухоли яичников. Л., 1961.5. Прокопенко П.Г., Борисенко С.А., Полторанина В.С. и др. Опухоли яичников: особенности эволюции, распространения, диагностики и профилактики. ОЖРС 2011;(1):63–9.Прокопенко П.Г., Борисенко С.А., Полторанина В.С. и др. Опухоли яичников: особенности эволюции, распространения, диагностики и профилактики. ОЖРС 2011;(1):63–9.6. Cliby W.A., Aletty G.D. et al. Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006;12(103):797–801.Cliby W.A., Aletty G.D. et al. Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006;12(103):797–801.7. Piver M.S., Marchetti D.L. Potential for cure in ovarian cancer. Comp Ther 1986; 12:13–20.Piver M.S., Marchetti D.L. Potential for cure in ovarian cancer. Comp Ther 1986; 12:13–20.8. Faber A.N., Rose P.G. Роль хирургии в лечении рака яичников. J Clin Oncol 2007;1(4):331–41.Faber A.N., Rose P.G. Роль хирургии в лечении рака яичников. J Clin Oncol 2007;1(4):331–41.9. Janni W. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis. Düsseldorf: Frauenklinik der Heinrich- Heine-Universitat.Janni W. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis. Düsseldorf: Frauenklinik der Heinrich- Heine-Universitat.10. Braun S et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 2001;19(2):368–75.Braun S et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 2001;19(2):368–75.11. Kaplan R.N., Riba R.D., Zacharoulis S. et al. VEGFR1 – positive haematopoetic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;8:(438):820–7.Kaplan R.N., Riba R.D., Zacharoulis S. et al. VEGFR1 – positive haematopoetic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;8:(438):820–7.12. Maffini M.V., Soto A.M., Callabro J.M. et al. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004;117:1495–502.Maffini M.V., Soto A.M., Callabro J.M. et al. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004;117:1495–502.13. Buys S.S., Partridge E., Black A. et al. Effect of screening on ovarian cancer mortality in the prostate, lung, color- ectal,ovarian cancer randomized screening trial. ASCO, 2011; abstr 5001.Buys S.S., Partridge E., Black A. et al. Effect of screening on ovarian cancer mortality in the prostate, lung, color- ectal,ovarian cancer randomized screening trial. ASCO, 2011; abstr 5001.14. Тамаева З.Э. Рецидивы рака яичника I–IIА стадии. Факторы прогноза, лечение. Автореф. дис. ... канд. мед. наук. М., 2005.Тамаева З.Э. Рецидивы рака яичника I–IIА стадии. Факторы прогноза, лечение. Автореф. дис. ... канд. мед. наук. М., 2005.15. Минимальные клинические рекомендации Европейского общества медицинской онкологии. Под ред. С.А. Тюляндина, Н.И. Переводчиковой, Д.А. Носова. М.: РОНЦ им. Н.Н. Блохина РАМН, 2007;с. 331–41.Минимальные клинические рекомендации Европейского общества медицинской онкологии. Под ред. С.А. Тюляндина, Н.И. Переводчиковой, Д.А. Носова. М.: РОНЦ им. Н.Н. Блохина РАМН, 2007;с. 331–41.16. Benedetti-Panici B., Maggioni A., Hacker N. et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560–6.Benedetti-Panici B., Maggioni A., Hacker N. et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560–6.17. Kim H., Ju W. et al. The efficacy of systemic lymphadenectomy for overal survival in epithelial ovarian cancer: a systematic review and meta-analysis by KOGYMAG. J Clin Oncol 2009;27; abstr 16509.Kim H., Ju W. et al. The efficacy of systemic lymphadenectomy for overal survival in epithelial ovarian cancer: a systematic review and meta-analysis by KOGYMAG. J Clin Oncol 2009;27; abstr 16509.18. Hoskins W.J., McGuire W.P., Brady M.F. et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170(4):974–80.Hoskins W.J., McGuire W.P., Brady M.F. et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170(4):974–80.19. Skirnisdottir I., Sorbe B. et al. Survival and prognostic factors in early-stage epithelial ovarian cancer treated with taxane-based adjuvant chemotherapy. Intern J Gynecol Cancer 2007.Skirnisdottir I., Sorbe B. et al. Survival and prognostic factors in early-stage epithelial ovarian cancer treated with taxane-based adjuvant chemotherapy. Intern J Gynecol Cancer 2007.20. Barrum-Gamez J. et al. Is there a high- risk subgroup of stage 1 of epithelial ovarian carcinoma that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Intern J Gynecol Cancer 2010;20(7).Barrum-Gamez J. et al. Is there a high- risk subgroup of stage 1 of epithelial ovarian carcinoma that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Intern J Gynecol Cancer 2010;20(7).21. Winter-Roach B., Hooper L., Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Intern J Gynecol Cancer 2003; 13(4):395–404.Winter-Roach B., Hooper L., Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Intern J Gynecol Cancer 2003; 13(4):395–404.